Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the 2022 Cell & Gene Meeting on the Mesa being held October 11-13, 2022 in Carlsbad, California and livestreamed globally. In addition, members from the management team will also be in attendance.

A pre-recorded presentation will be available on-demand starting Tuesday, October 11, 2022. Please visit https://meetingonthemesa.com for full information including registration.

About Talaris TherapeuticsTalaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.

Media ContactLisa RaffenspergerTen Bridge Communicationslisa@tenbridgecommunications.com(617) 903-8783

Investor ContactChris BrinzeyICR Westwickechris.brinzey@westwicke.com(339) 970-2843

Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Talaris Therapeutics Charts.
Talaris Therapeutics (NASDAQ:TALS)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Talaris Therapeutics Charts.